Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat

Bibliographic Details
Title: Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat
Authors: David S. Mathiesen, Asger Lund, Tina Vilsbøll, Filip K. Knop, Jonatan I. Bagger
Source: Frontiers in Endocrinology, Vol 11 (2021)
Publisher Information: Frontiers Media S.A., 2021.
Publication Year: 2021
Collection: LCC:Diseases of the endocrine glands. Clinical endocrinology
Subject Terms: amylin, calcitonin, dual amylin-calcitonin receptor agonist, DACRA, NAFLD, non-alcoholic fatty liver disease, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
More Details: The hormones amylin and calcitonin interact with receptors within the same family to exert their effects on the human organism. Calcitonin, derived from thyroid C cells, is known for its inhibitory effect on osteoclasts. Calcitonin of mammalian origin promotes insulin sensitivity, while the more potent calcitonin extracted from salmon additionally inhibits gastric emptying, promotes gallbladder relaxation, increases energy expenditure and induces satiety as well as weight loss. Amylin, derived from pancreatic beta cells, regulates plasma glucose by delaying gastric emptying after meal ingestion, and modulates glucagon secretion and central satiety signals in the brain. Thus, both hormones seem to have metabolic effects of relevance in the context of non-alcoholic fatty liver disease (NAFLD) and other metabolic diseases. In rats, studies with dual amylin and calcitonin receptor agonists have demonstrated robust body weight loss, improved glucose tolerance and a decreased deposition of fat in liver tissue beyond what is observed after a body weight loss. The translational aspects of these preclinical data currently remain unknown. Here, we describe the physiology, pathophysiology, and pharmacological effects of amylin and calcitonin and review preclinical and clinical findings alluding to the future potential of amylin and calcitonin-based drugs for the treatment of obesity and NAFLD.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1664-2392
Relation: https://www.frontiersin.org/articles/10.3389/fendo.2020.617400/full; https://doaj.org/toc/1664-2392
DOI: 10.3389/fendo.2020.617400
Access URL: https://doaj.org/article/850e3478799943b99a097ab97e309591
Accession Number: edsdoj.850e3478799943b99a097ab97e309591
Database: Directory of Open Access Journals
More Details
ISSN:16642392
DOI:10.3389/fendo.2020.617400
Published in:Frontiers in Endocrinology
Language:English